# Deng Ning

> Deng Ning is a seed investor at Dingxin Capital backing Therapeutics and Medical. See 4 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Dingxin Capital](https://shizune.co/investors/profile/dingxin-capital)
- Total investments: 4
- Last investment: Jan 2026
- Lead investor: 25%
- Last updated: Aug 2026

Deng Ning is a seed investor at Dingxin Capital focused on Therapeutics and Medical. Deng Ning is the partner of Dingxin Capital.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Therapeutics | 3 | 75% |
| Medical | 2 | 50% |
| Health Care | 2 | 50% |
| Medical Device | 2 | 50% |
| Pharmaceutical | 2 | 50% |

7 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 2 | 50% |
| Series B | 1 | 25% |
| Series D | 1 | 25% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Xingaotopi | Xingaotopi focuses on the innovative development of novel therapeutic drugs for sensorineural hearing loss, aiming to restore auditory function and improve quality of life through advanced biomedical research and cutting-edge treatment technologies. | $14.3M | Seed | Jan 04, 2026 |  |
| Reju Therapeutics | Reju Therapeutics, a biopharmaceutical company, is dedicated to research and development of drugs for treating degenerative diseases like neurodegenerative, fibrotic, and inflammatory conditions. |  | Seed | May 08, 2024 |  |
| Brattea | Brattea is a medical device research and development company. Brattea focuses on the development and commercialization of renal denervation products with indications in hypertension, cancer pain and diabetes. |  | Series D | Mar 25, 2024 |  |
| Ruining Bio | Ruining Bio provides clinical medical solutions such as tumor radiotherapy protection, wound repair, tumor embolization, and anti-tumor drugs. Ruining Bio brings together various professionals in materials, chemistry, biomedical engineering, and clinical medicine. | $8.5M | Series B | Jan 24, 2024 |  |

4 of 4 investments shown.

## Co-investors
- [Longpan Investment](https://shizune.co/investors/profile/longpan-investment) — VC Fund, 2 deals together
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund, 2 deals together
- [Delian Capital](https://shizune.co/investors/profile/delian-capital) — VC Fund, 1 deal together
- [Guosen Innovation Equity](https://shizune.co/investors/profile/guosen-innovation-equity) — VC Fund, 1 deal together
- [Morning Spring Venture](https://shizune.co/investors/profile/morning-spring-venture) — VC Fund, 1 deal together
- [Nanjing Innovation Capital Group](https://shizune.co/investors/profile/nanjing-innovation-capital-group) — VC Fund, 1 deal together

## About Dingxin Capital

VC Fund · Shenzhen, China

Dingxin Capital is an investment management agency that specializes in equity investments. The partners are mainly from domestic first-line investment institutions such as CDH, Jiuding and Zhongjin. They have deep accumulation and rich experience in the equity investment field, paying attention to the construction of the whole organization andtrying to build a truly sustainable competition. Investment institutions.

4 contacts available at Dingxin Capital.

| Name | Title | Profile |
| --- | --- | --- |
| Deng Ning | Partner | https://shizune.co/investors/profile/deng-ning-5672 |
| Hu Hui | Founding partner | https://shizune.co/investors/profile/hu-hui-c320 |
| Yu Kang | Senior Investment Manager | https://shizune.co/investors/profile/yu-kang |
| Zhou Zhou | Senior Partner | https://shizune.co/investors/profile/zhou-zhou-522c |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Deng Ning invest in?

Deng Ning invests primarily in Therapeutics, Medical and Health Care startups, most often at Seed and Series B stage. Most of the 4 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Deng Ning last invest?

The most recent investment recorded for Deng Ning closed in Jan 2026. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co